Immediate Impact
65 standout
Citing Papers
GPCR drug discovery: new agents, targets and indications
2025 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Works of Elsa M. Li-Ning-Tapia being referenced
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy
2023
CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment
2016
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Elsa M. Li-Ning-Tapia | 125 | 75 | 139 | 90 | 6 | 296 | |
| Bi-Yun Wang | 71 | 93 | 65 | 81 | 6 | 242 | |
| Kimberly B. Monahan | 173 | 170 | 89 | 51 | 6 | 319 | |
| Long-Zi Liu | 107 | 96 | 72 | 81 | 8 | 318 | |
| Tiening Zhang | 95 | 162 | 67 | 115 | 9 | 319 | |
| Joanna Vitfell-Rasmussen | 134 | 163 | 92 | 38 | 6 | 332 | |
| Feiying Gu | 102 | 126 | 92 | 52 | 11 | 297 | |
| Leigh J. Hodson | 177 | 77 | 55 | 74 | 8 | 315 | |
| Ellen C. de Heer | 107 | 165 | 68 | 136 | 8 | 332 | |
| Ram C. Shankaraiah | 93 | 185 | 55 | 147 | 10 | 331 | |
| Alexandra H. Besser | 112 | 122 | 30 | 94 | 6 | 277 |
All Works
Login with ORCID to disown or claim papers
Loading papers...